Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
about
DIPG in Children - What Can We Learn from the Past?Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstemChildhood brain tumors: epidemiology, current management and future directions.Initial testing of topotecan by the pediatric preclinical testing program.Management of diffuse pontine gliomas in children: recent developments.Brainstem glioma: a review.A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.Genotoxic Damage to Glioblastoma Cells Treated with 6 MV X-Radiation in The Presence or Absence of Methoxy Estradiol, IUDR or Topotecan.Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.Diffuse intrinsic pontine glioma: poised for progress.Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail.Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.Diffuse intrinsic pontine glioma: time for therapeutic optimism.Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.Survival with concurrent temozolomide and radiotherapy in pediatric brainstem glioma with relation to the tumor volume.Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.DNA damage of glioblastoma multiform cells induced by Beta radiation of iodine-131 in the presence or absence of topotecan: a picogreen and colonogenic assayThe potential of theragnostic ¹²⁴I-8H9 convection-enhanced delivery in diffuse intrinsic pontine gliomaExpression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas.Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG.Pediatric diffuse intrinsic pontine glioma patients from a single center.A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
P2860
Q26777843-BDCEF509-79C4-44A1-9AD8-0CAC19BFE427Q33796170-24EE432D-708A-4E5A-BDF4-0E871F363059Q33970971-55CBC25E-B430-4104-A8E5-077A7530D50EQ34073784-71AED29D-E0E7-4705-9A74-1E6983437016Q34347540-69AC7694-CE01-4D19-BFF7-0CD54A6836D1Q34628180-FFA3BEC8-E5AC-4E69-BCF5-D5CF24C42D47Q34722457-608EC760-26C8-4942-AE6D-EDC7B9BF4101Q34722864-16092EEB-2BDC-4259-A9FA-936B2B1EDF0BQ35856038-4230565B-580A-495A-A5EA-B93DEFE2B0BAQ36485991-0BB9308F-5D2D-4694-996B-62762C6299AFQ36492719-64118C7A-09AA-4171-8502-5B8A818ACD90Q36817114-D49A7439-9CAC-48F3-B84D-6B91A458D9CCQ37151985-F0FCA9CD-35D3-47CD-9F95-F1AD5E50E3FBQ37152041-C204FBFA-E572-491F-A688-7CD664BB08ABQ37311185-67CE4EAA-D581-49CF-821F-4A7487FC5371Q38264309-47927CCB-0126-4D7D-823E-A1E0E1D9C93AQ38586537-378FFAB2-1A56-4F80-A7D3-B05817BA6427Q38672647-9ADDBAF5-7157-4642-9DF5-8C49F1D62C6EQ38960333-0CA4A1B5-4E96-4299-BA69-8896C7F26D10Q39217689-6D86D84E-6D26-42C6-AEF2-12159B6D9E7BQ39385101-3EE7595F-6699-476F-B6B0-12E889704EF0Q39527014-2E7A6347-0A38-448E-B555-FB796155468BQ39645468-016E1323-D8A9-4B50-AD24-44C597FAEA9FQ41811462-6961D163-11EB-4A27-86A5-41ED4326D140Q45384951-7F8521F5-DE88-4038-A8AB-55C70F55D9FCQ46497829-6FB4A4AA-EE2E-4AE5-8246-DB5C6C5FA76AQ47992039-C9D42A5C-7390-43F9-8D51-3AE1695009F0Q48190337-2F3FE7D2-17C4-4AD7-BD26-EDFE3295DF91
P2860
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@en
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@nl
type
label
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@en
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@nl
prefLabel
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@en
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@nl
P2093
P2860
P356
P1433
P1476
Topotecan as a radiosensitizer ...... atric Oncology Phase II Study.
@en
P2093
A Marie-Cardine
F Mechinaud
Francois Doz
G Margueritte
Jean Claude Gentet
Pascal Chastagner
P2860
P304
P356
10.1002/CNCR.21534
P407
P577
2005-12-01T00:00:00Z